Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

September’s top news stories

Emerald Health Pharmaceuticals (EHP) started patient enrolment for its Phase I clinical trial of EHP-101 for the treatment of patients with multiple sclerosis (MS) and scleroderma, and Ra Pharmaceuticals reported positive data from the Phase lb trial examining the pharmacokinetic (PK) of zilucoplan (RA101495 SC) to treat patients with renal impairment. Drugdevelopment-technology.com wraps up the key news stories from September 2018.

Go Top